Ablynx Successfully Raises €31.5 Million, in Total €45 Million Placed - Gilde Healthcare

Ablynx Successfully Raises €31.5 Million, in Total €45 Million Placed

February 28, 2013

REGULATED INFORMATION

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies®, announces today that it has raised €31.5 million through a private placement of new shares via an accelerated bookbuilding procedure announced on Wednesday 27 February 2013 after the market closed.

The private placement has allowed Ablynx to place 4,377,919 new shares with a range of domestic and international institutional investors and qualified institutional buyers in the United States at a price of €7.2 per share, a 6.7% discount on the previous closing price. This represents 10.0% of the current number of outstanding shares and will bring the total number of shares after the issue to 48,157,116. The new shares will be admitted to trading on NYSE Euronext Brussels following their issuance, which is expected to take place on 5 March 2013.

The private placement was oversubscribed and certain pre-IPO shareholders and warrant holders sold 1,872,081 shares at the same price in conjunction with this transaction.

The funds will be used by Ablynx to:

  • maintain the momentum of ALX-0061 and review paths (e.g. co-development, fund additional clinical trials, retain (co-) promotion rights) which could allow the value of this asset to be maximized;
  • allow flexibility in the structure and timing of any potential deals to license clinical assets such as caplacizumab (anti-vWF) and ALX-0171 (anti-RSV);
  • initiate, advance and/or accelerate the pre-clinical development for wholly- and co-owned programmes with a broad range of risk-return profiles; and
  • for general corporate purposes.

KBC Securities NV acted as Global Coordinator. KBC Securities NV, Bryan, Garnier & Co. Limited and Nomura Code Securities Limited acted as Joint Bookrunners for the placement.

Dr Edwin Moses, Chairman and CEO of Ablynx commented:

“We are very pleased to announce the successful completion of the private placement which we believe reflects the strong progress made at Ablynx over the past year. The new funds will give us increased flexibility to invest in our Nanobody pipeline and in particular to build on the successful Phase II results of our rheumatoid arthritis product, ALX-0061, announced earlier this month. We are grateful to our existing shareholders for their continuing support and welcome our new investors. We believe that Ablynx is well placed to deliver significant value to shareholders in the coming years and we look forward to updating them on our progress during 2013.”

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
November 25, 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024